Blar i forfatter "Zitvogel, Laurence"

Viser treff 1-5 av 5

    • Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 

      Galluzzi, Lorenzo; Vitale, Ilio; Warren, Sarah; Adjemian, Sandy; Agostinis, Patrizia; Martinez, Aitziber Burque; Chan, Timothy A.; Coukos, George; Demaria, Sandra; Deutsch, Eric; Draganov, Dobrin; Edelson, Richard L; Formenti, Silvia C.; Fucikova, Jitka; Gabriele, Lucia; Gaipl, Udo S.; Gameiro, Sofia R.; Garg, Abhishek D.; Golden, Encouse; Han, Jian; Harrington, Kevin J.; Hemminki, Akseli; Hodge, James W.; Hossain, Dewan Md Sakib; Illidge, Tim; Karin, Michael; Kaufman, Howard L.; Kepp, Oliver; Kroemer, Guido; Lasarte, Juan Jose; Loi, Sherene; Lotze, Michael T.; Manic, Gwenola; Merghoub, Taha; Melcher, Alan A.; Mossman, Karen L.; Prosper, Felipe; Rekdal, Øystein; Rescigno, Maria; Riganti, Chiara; Sistigu, Antonella; Smyth, Mark J.; Spisek, Radek; Stagg, John; Strauss, Bryan E.; Tang, Daolin; Tatsuno, Kazuki; van Gool, Stefaan W.; Vandenabeele, Peter; Yamazaki, Takahiro; Zamarin, Dmitriy; Zitvogel, Laurence; Cesano, Alessandra; Marincola, Francesco M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-03-09)
      Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death ...

    • Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals 

      Zhou, Heng; Mondragón, Laura; Xie, Wei; Mauseth, Brynjar; Leduc, Marion; Sauvat, Allan; Gomes-da-Silva, Lígia C.; Forveille, Sabrina; Iribarren, Kristina; Souquere, Sylvie; Bezu, Lucillia; Liu, Peng; Zhao, Liwei; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Eksteen, Jacobus Johannes; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-23)
      Abstract Oncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 ...

    • The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization 

      Zhou, Heng; Forveille, Sabrina; Sauvat, Allan; Sica, Valentina; Izzo, Valentina; Durand, Sylvère; Müller, Kevin; Liu, Peng; Zitvogel, Laurence; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-09-10)
      LTX-315 has been developed as an amphipathic cationic peptide that kills cancer cells. Here, we investigated the putative involvement of mitochondria in the cytotoxic action of LTX-315. Subcellular fractionation of LTX-315-treated cells, followed by mass spectrometric quantification, revealed that the agent was enriched in mitochondria. LTX-315 caused an immediate arrest of mitochondrial ...

    • The oncolytic peptide LTX-315 triggers immunogenic cell death 

      Zhou, Heng; Forveille, Sabrina; Sauvat, Allan; Yamazaki, T; Senovilla, L; Ma, Y; Liu, Peng; Yang, H; Bezu, L; Müller, K; Zitvogel, Laurence; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-03-10)
      LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/ BAK1-regulated, caspase-independent necrosis. Based on the observation that intratumorally injected LTX-315 stimulates a strong T lymphocyte-mediated anticancer immune response, we investigated whether LTX-315 may elicit the hallmarks of immunogenic cell death (ICD), ...

    • Tumor lysis with LTX-401 creates anticancer immunity 

      Xie, Wei; Mondragon, Laura; Mauseth, Brynjar; Wang, Yan; Pol, Jonathan; Levesque, Sarah; Zhou, Heng; Yamazaki, Takahiro; Eksteen, Jacobus Johannes; Zitvogel, Laurence; Sveinbjørnsson, Baldur; Rekdal, Øystein; Kepp, Oliver; Kroemer, Guido (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-13)
      Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and ...